Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,665 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Phase 2Phase 3 Interventional Results available

Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment

NCT02055118
View directory record Official record
Conditions
Hunter Syndrome
Interventions
idursulfase-IT, No IT treatment
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
Up to 18 Years · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Oakland, California • Chicago, Illinois • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 22, 2026, 9:19 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

NCT00780325
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CG100649 (2 mg), Celecoxib, Placebo capsules, Naproxen, Acetazolamide, CG100649 (8 mg)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 22, 2026, 9:19 AM EDT
Withdrawn Phase 2 Interventional

Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy

NCT00004040
View directory record Official record
Conditions
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
recombinant interferon alfa, rituximab
Biological
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 1999
U.S. locations
3
States / cities
Newport Beach, California • Knoxville, Tennessee • Bryan, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 22, 2026, 9:19 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

NCT06316297
View directory record Official record
Conditions
Acne
Interventions
Acne mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
79
States / cities
Scottsdale, Arizona • Cerritos, California • Encino, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 9:19 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Novel Mobile Health Intervention for Improving Tobacco Cessation Among Young Adults

NCT07571018
View directory record Official record
Conditions
Tobacco-Related Carcinoma
Interventions
Smartphone app-based Intervention, Communication intervention, Survey Administration, Interview, Assessment
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 30 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Las Cruces, New Mexico • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 9:19 AM EDT
Recruiting Not applicable Interventional

Influence of Spinal Stimulation Frequency on Spasticity, Motor Control, and Pain After Spinal Cord Injury

NCT06214208
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Transcutaneous Spinal Stimulation
Other
Lead sponsor
Shepherd Center, Atlanta GA
Other
Eligibility
16 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 22, 2026, 9:19 AM EDT
Terminated Phase 2 Interventional Results available

Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

NCT03087708
View directory record Official record
Conditions
Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
Naloxegol, Placebo, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
660
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 407 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 22, 2026, 9:19 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

NCT00000989
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Zidovudine, Sargramostim, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 9:19 AM EDT
Completed Phase 3 Interventional

Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS

NCT00021697
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
17
States / cities
Loma Linda, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 22, 2026, 9:19 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid

NCT00742417
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Albutein 5%, Control
Biological · Other
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Whiting, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 22, 2026, 9:19 AM EDT
Completed Not applicable Interventional

Impact of the Relaxation Response Resiliency Program on Patients With Atrial Fibrillation

NCT02634697
View directory record Official record
Conditions
Atrial Fibrillation, Stress, Quality of Life, Anxiety, Depression, Hostility
Interventions
Relaxation Response Resiliency Program
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 22, 2026, 9:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome

NCT04977388
View directory record Official record
Conditions
Menkes Disease, Occipital Horn Syndrome
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
Stephen G. Kaler, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 22, 2026, 9:19 AM EDT
Completed Phase 2 Interventional Results available

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

NCT03859973
View directory record Official record
Conditions
Schizophrenia
Interventions
BI 425809, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Encino, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 22, 2026, 9:19 AM EDT
Completed No phase listed Observational

Hypertrophic Cardiomyopathy Pilot Study

NCT02806479
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Coronary Artery Disease
Interventions
Observational: Arrhythmogenic Substrate
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 22, 2026, 9:19 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)

NCT07477418
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms
Interventions
Gemcitabine Delivered by Transarterial Microperfusion
Combination Product
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 22, 2026, 9:19 AM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis

NCT00726479
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Interventions
BIBW 2948 BS
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
8
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 22, 2026, 9:19 AM EDT
Completed Phase 2 Interventional Results available

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

NCT05162586
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Torrance, California • Brandon, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 22, 2026, 9:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors

NCT01272570
View directory record Official record
Conditions
Breast Cancer, Xerostomia
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 22, 2026, 9:19 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

RESTORE - Phase II

NCT06349070
View directory record Official record
Conditions
Maternal Health
Interventions
Low Touch - Text Messaging Implementation Strategy, High Touch - Community Health Worker (CHW) Implementation Strategy
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
1,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 22, 2026, 9:19 AM EDT
Withdrawn Not applicable Interventional

Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy

NCT00084370
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
Interventions
celecoxib, oophorectomy
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 22, 2026, 9:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neurobiology and Treatment of Reading Disability in NF-1

NCT00624234
View directory record Official record
Conditions
Neurofibromatosis Type 1, Reading Disabilities
Interventions
Tutoring Program I, Tutoring Program II
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
8 Years to 17 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 22, 2026, 9:19 AM EDT
Completed Phase 2 Interventional Results available

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

NCT01537432
View directory record Official record
Conditions
Psoriasis, Plaque-type Psoriasis
Interventions
secukinumab, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Birmingham, Alabama • Pasadena, California • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 22, 2026, 9:19 AM EDT
Terminated Phase 2 Interventional Results available

Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients

NCT04398199
View directory record Official record
Conditions
Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III
Interventions
Hypofractionated Radiation Therapy, Radiation Boost
Drug · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 22, 2026, 9:19 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression

NCT02300987
View directory record Official record
Conditions
Teratoma
Interventions
LEE011, LEE011 Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
15 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Albuquerque, New Mexico • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 22, 2026, 9:19 AM EDT